ONCOassist

09/10/2025

🧮Calculate CPS+EG Breast Cancer Prognostic Score in seconds with ONCOassist

🔗App Download Link in Bio

09/10/2025

🚨 FDA Approval Alert!

✅ Libtayo® (cemiplimab-rwlc) is now the first and only immunotherapy approved in the U.S. for adjuvant treatment of high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation.

📊 Phase III C-POST trial showed Libtayo reduced the risk of recurrence or death by 68% vs. placebo, marking a potential shift in the CSCC treatment paradigm.

🔗 Read more: bit.ly/ONCOnews09O-1

08/10/2025

How do you access NCCN guidelines for free?
Katy Winckworth-Prejsnar shares how easy it is and how ONCOassist helps take these tools global. 🌍📲

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://bit.ly/oncoassistonandroid
📥Webapp: https://bit.ly/ONCOassistOnWeb

08/10/2025

🌐 AI platforms like ChatGPT & Gemini spotlight ONCOassist as the go- to oncology app worldwide.

✅ Trusted by 100,000+ Oncology Health Care Professionals across the globe
✅ Powered by evidence-based tools
✅ Designed to make daily practice simpler & more effective

📲 Your all-in-one oncology app, crafted for oncology professionals.

⬇️ If you’re an HCP, download our app now : http://bit.ly/download_ONCOassist_app

07/10/2025

🎥 Oncology Bytes | Managing ADC Toxicities

Michele Maffezzoli,MD, discusses key insights from a global survey of 1,200+ clinicians across 180+ countries, conducted via the ONCOassist app.
Discover the disparities in confidence levels across regions, specialities, and roles—and why it matters for your patients.

🎥 Watch the full breakdown: https://youtu.be/t8mHHX2--yE

Access the published research below:
🔗 https://academic.oup.com/oncolo/article/30/9/oyaf232/8215414

🌐 Learn more at: https://oncoassist.com/

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://bit.ly/oncoassistonandroid
📥Webapp: https://bit.ly/ONCOassistOnWeb

🎥 Oncology Bytes | Dr. Michele MaffezzoliIn this clip of Oncology Bytes, Michele Maffezzoli, MD, at the University Hospital of Parma, breaks down findings f...

07/10/2025

🎗️BREAKING: Phase III Results!

💊 AstraZeneca & Daiichi Sankyo’s Datroway (datopotamab deruxtecan) becomes the first and only therapy to show a significant overall survival benefit vs. chemotherapy in patients with metastatic triple-negative breast cancer ineligible for immunotherapy.

📈 The treatment also showed a highly significant improvement in progression-free survival in the TROPION-Breast02 trial.

🔗 Read more: bit.ly/ONCOnews07O-1

06/10/2025

🧰 Discover Metastatic Castrate Resistant Prostate Cancer Tool in ONCOassist!

Have you tried the mCRPC Tool yet? Designed to support oncology professionals treating metastatic castration-resistant prostate cancer.

✨ Key features:

✅ Side-by-side comparison of novel mCRPC therapies
📊 Data from the latest clinical trials
🕒 Quick access to PFS & OS outcomes
🎯 Supports treatment planning across therapy lines
💡 Streamline your workflow & enhance decision-making in mCRPC care.

🔗 Click here to access the tool now 👉 bit.ly/ONCOassist_mCRPC_Tool

03/10/2025

🚨 FDA Approval Alert !

✅ Roche’s Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with Zepzelca® (lurbinectedin) approved as the first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC).

📊 In the Phase III IMforte study, the combo reduced the risk of disease progression or death by 46% and the risk of death by 27%.

🔗 Read more: bit.ly/ONCOnews3O-1

02/10/2025

🌍 “Where you live shouldn’t determine if you live.”
In this moving moment, Katy Winkworth-Prejsnar from shines a light on the global disparities in cancer outcomes.

🎥 Watch this powerful reflection from her full episode on , now live!
🔗 Link in bio to full conversation
👩⚕️ Powered by

01/10/2025

Wright GFR-based dosing, simplified.

The ONCOassist app lets you calculate Carboplatin dose using the Wright equation for GFR in seconds.

📲 Try the Wright-based calculator now in ONCOassist.

🔗App Download Link in Bio



[Oncology Tools, Carboplatin Dose Calculator, Wright equation, Best Oncology App]

30/09/2025

🚨Clinical Update – Uterine Cancer!

🧬 Signatera™ is a personalized ctDNA test that detects molecular residual disease (MRD) by identifying tiny traces of tumor DNA in the blood. It’s custom-designed for each patient to monitor for recurrence.

🔬 In a recent study, Signatera™ identified 100% of uterine cancer recurrences before imaging, with a median lead time of 3.1 months.

📊 It was the most prognostic risk factor, outperforming traditional clinicopathologic factors.

🔗 Read more: bit.ly/ONCOnews30S-3

30/09/2025

🌍 How do you make cancer guidelines work for every region, no matter the resources?

In our latest Oncology Spotlight episode, we speak with Katy Winckworth-Prejsnar, Director of the Global Program at NCCN, about how they're working to make high-quality cancer care a global standard.

From local adaptations of NCCN Guidelines to building policy and advocacy collaborations, Katy’s work is changing the landscape for patients in low- and middle-income countries.

🎧 Tune in now to hear about:

✔️ Global adaptation of NCCN Guidelines
✔️ Cancer equity in action
✔️ The role of outreach, education, and policy
🔗 Watch here: https://youtu.be/sP4biZu-dHs

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://bit.ly/oncoassistonandroid
📥Webapp: https://bit.ly/ONCOassistOnWeb

🌐 Explore ONCOassist – clinical tools for oncology professionals: https://oncoassist.com/

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators! 🔬In this episode of Oncology Spotlight, we...